Germany: IQWiG Finds Melanoma Drug Extends Life
| Posted: 3 May 2012
By Louise Zornoza, RegLink
A comparator study undertaken by Germany's Institute for Quality and Economy in Healthcare (IQWiG) has found the drug ipilimumab provides substantial additional benefit to patients suffering from advanced melanoma.
In a three-pronged randomized clinical trial against “best supportive care”, IQWiG found the drug extended life expectancy by 10 months as compared to 6.5 months with the comparator.
The drug, however, is not without serious immune-mediated side effects as well.
IQQiG - Ipilimumab – Nutzenbewertung gemäß § 35a SGB V
More Breaking News from RegLink